Vitamin B6
Pyridoxine / Pyridoxal-5-Phosphate (P5P)
Key Benefits
Mood Regulation
Required for serotonin, dopamine, and GABA synthesis, supporting mental health and emotional balance.
Energy Metabolism
Involved in glycogen breakdown and amino acid metabolism for energy production.
Homocysteine Reduction
Works with B12 and folate to convert homocysteine, reducing cardiovascular risk.
Activation Synergies
B6 enhances magnesium absorption and cellular uptake.
B6 is required for converting tryptophan to melatonin, supporting natural melatonin production and sleep regulation.
Both work together in homocysteine metabolism and neurotransmitter synthesis.
Recommended Dosage
medical_servicesP5P (pyridoxal-5-phosphate) is active form, better for those with conversion issues. High doses (>200mg long-term) may cause neuropathy. Take with other B vitamins.
Deficiency Indicators
- Depression or irritability
- Confusion or brain fog
- Weakened immunity
- Anemia (microcytic)
Scientific Citations
Vitamin B6 Fact Sheet
Research & Sources
What the evidence says — with links to the original studies
Vitamin B6 is an essential water-soluble vitamin whose active coenzyme form, pyridoxal 5'-phosphate (PLP), participates in more than 100 enzymatic reactions, chiefly amino acid, glucose and lipid metabolism, neurotransmitter synthesis (serotonin, GABA, dopamine) and one-carbon/homocysteine metabolism. Evidence is strongest and consensus-backed for two clinical uses: (1) pyridoxine as an ACOG first-line therapy for nausea and vomiting of pregnancy (NVP/morning sickness), supported by randomized trials and a 2023 systematic review/meta-analysis; and (2) modest symptom relief in premenstrual syndrome (PMS) at doses up to 100 mg/day (Wyatt BMJ 1999 systematic review), though trial quality is low. Vitamin B6 lowers plasma homocysteine, especially alongside folate and B12, but large randomized trials (HOPE-2, NORVIT, others) show homocysteine lowering with B-vitamins does NOT reduce cardiovascular events or mortality, so it is not recommended for CVD prevention. Critical safety concern: chronic high-dose pyridoxine causes a dose-dependent, sensory-predominant peripheral neuropathy/neuronopathy (stocking-glove numbness, ataxia); the adult Tolerable Upper Intake Level is 100 mg/day. Deficiency is uncommon in isolation. Pyridoxine (HCl) and PLP are the main supplement forms; PLP is the metabolically active coenzyme but pyridoxine is the most common and well-absorbed supplement form.
Supporting Evidence
Authoritative reference. PLP/PMP are active coenzyme forms in 100+ reactions. Adult RDA 1.3-1.7 mg/day; Tolerable Upper Intake Level (UL) = 100 mg/day for adults. States chronic 1-6 g/day pyridoxine for 12-40 months causes severe progressive sensory neuropathy with ataxia; notes B6 supplementation alone has not proven effective for reducing CVD risk. Open access.
18 trials; pyridoxine alone and in combination significantly improved nausea by Rhodes score (SMD 0.78, 95% CI 0.26-1.31, p=0.003) and PUQE score (0.75, 95% CI 0.28-1.22, p=0.002). Supports B6 for NVP. Abstract open; full text paywalled.
ACOG recommends vitamin B6 (pyridoxine) monotherapy or pyridoxine plus doxylamine as safe and effective first-line pharmacologic treatment for nausea and vomiting of pregnancy. Guideline abstract open access; PubMed PMID 29266076.
Meta-analysis of 9 RCTs (940 participants). Pooled odds ratio favoring B6 over placebo 2.32 (95% CI 1.95-2.54) for overall symptoms; 1.69 (1.39-2.06) for premenstrual depression. Concluded doses up to 100 mg/day likely beneficial, but flagged low quality of included trials. Open-access NCBI Bookshelf record.
Foundational RCT (n=59) showing pyridoxine 25 mg every 8 hours significantly reduced severe nausea versus placebo. Underpins ACOG first-line recommendation. Abstract open access.
Confirms coenzyme role and dose-dependent sensory peripheral neuropathy: symptoms typically above 1000 mg/day, cases below 500 mg, none below 200 mg/day; stocking-glove numbness, ataxia. Usually reversible within ~6 months of discontinuation but some patients do not fully recover. Open access.
Opposing / Critical Views
RCT (~5,522 patients) of folic acid + B6 + B12. Lowered homocysteine but did NOT reduce the composite of cardiovascular death, MI, or stroke. Undercuts using B6/homocysteine lowering for CVD prevention. Abstract open access (PMID 16531613).
Safety/toxicity source. Documents pyridoxine-induced sensory ataxic neuronopathy (dorsal root ganglionopathy) from chronic high-dose supplementation, sometimes at doses lower than historically assumed; recovery may be incomplete. Reinforces UL of 100 mg/day. Abstract open access.
Full-text & official documents
Educational summary of published research — not medical advice. Consult a qualified professional before supplementing.
Have You Tried This?
Join our collective laboratory. Share your experience level with this topic and help others gauge the journey.
Based on .
No one has shared yet. Be the first to place a pin on the map.
check_circle You marked yourself as .
Status: In Your Stack Status: Not in Stack